Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives $24.00 Average Price Target from Analysts

Artelo Biosciences, Inc. (NASDAQ:ARTL) has been assigned a consensus recommendation of “Hold” from the four brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $24.00.

A number of equities research analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Monday, December 29th. Maxim Group reissued a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th.

Artelo Biosciences Price Performance

Shares of ARTL stock opened at $1.47 on Friday. The firm’s 50-day moving average is $1.62 and its two-hundred day moving average is $4.47. Artelo Biosciences has a 12 month low of $1.15 and a 12 month high of $28.60. The company has a market capitalization of $2.97 million, a PE ratio of -0.07 and a beta of 1.13.

Artelo Biosciences (NASDAQ:ARTL) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($3.97) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($3.15). Sell-side analysts forecast that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.